UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
Form
6-K
Report
of Foreign Private Issuer
Pursuant
to Rule 13a-16 or 15d-16
of
the Securities Exchange Act of 1934
For
the
month of October 2008
Commission
File Number: 000-51310
XTL
Biopharmaceuticals Ltd.
(Translation
of registrant's name into English)
711
Executive Blvd., Suite Q
Valley
Cottage, New York 10989
(Address of principal executive offices)
Indicate
by check mark whether the registrant files or will file annual reports under
cover Form 20-F or Form 40-F.
Form
20-F x Form
40-F
Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted
by Regulation S-T Rule
101(b)(1):
Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted
by Regulation S-T Rule
101(b)(7):
Indicate
by check mark whether by furnishing the information contained in this Form,
the
registrant is also thereby furnishing the information to the Commission pursuant
to Rule 12g3-2(b) under the Securities Exchange Act of 1934.
Yes No x
If
“Yes”
is marked, indicate below the file number assigned to the registrant in
connection with Rule 12g3-2(b): 82-
N/A
Incorporation
by Reference: This Form 6-K of XTL Biopharmaceuticals Ltd. dated October 7,
2008
is hereby incorporated by reference into the registration statements on Form
F-3
(File No. 333-141529, File No. 333-147024 and File No. 333-153055) filed by
XTL
Biopharmaceuticals Ltd. with the Securities and Exchange Commission on March
23,
2007 , October 30, 2007 and August 15, 2008, respectively, and the registration
statements on Form S-8 (File No. 333-148058 and File No. 333-148574) filed
by
XTL Biopharmaceuticals Ltd. with the Securities and Exchange Commission on
December 14, 2007 and January 18, 2008, respectively.
Extraordinary
General Meetings Statement
—
XTL Notifies NASDAQ of Compliance with Marketplace Rule
4350(d)(2)
Valley
Cottage, New York, October 10, 2008
- XTL
Biopharmaceuticals Ltd. (NASDAQ: XTLB; TASE: XTL) announces the results of
its
Extraordinary General Meetings (“EGMs”) held earlier today.
The
outcome of the EGMs was as follows: all of the resolutions passed and Jennifer
L. Good and Kenneth J. Zuerblis were appointed as External Directors of the
Company until October 10, 2011. Following the EGMs, XTL’s Audit Committee
consists of Mr. Zuerblis, Ms. Good and Dr. William Kennedy.
With
the
election of the External Directors by the shareholders and their automatic
inclusion in the Audit Committee, XTL has notified NASDAQ that it currently
has
a valid Audit Committee under the Israeli Companies Act and NASDAQ Marketplace
Rule 4350(d)(2).
ABOUT
XTL
BIOPHARMACEUTICALS LTD.
XTL
Biopharmaceuticals Ltd. (“XTL”) is engaged in the development of therapeutics
for the treatment of diabetic neuropathic pain and HCV. XTL is developing
Bicifadine, a triple reuptake inhibitor of serotonin, norepinephrine and
dopamine, which is currently in a Phase 2b study for the treatment of diabetic
neuropathic pain. XTL has out-licensed its novel pre-clinical HCV small molecule
inhibitor program. XTL is publicly traded on the NASDAQ and Tel-Aviv Stock
Exchanges (NASDAQ: XTLB; TASE: XTL).
Contact:
Ron
Bentsur, Chief Executive Officer
Tel:
+1-(845)-267-0707 ext. 225
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, as amended, the
registrant has duly caused this report to be signed on its behalf by the
undersigned, thereunto duly authorized.
|
XTL BIOPHARMACEUTICALS LTD.
|
||
|
By:
|
/s/
Ron Bentsur
|
|
|
Ron
Bentsur
|
||
|
Chief Executive Officer
|
||